Harrow (HROW) Stock Price
Harrow Price
Over the last 13 years Harrow grew revenue by 83.8% annually, reaching 272.30 M USD. For Harrow, the net margin of -1.9% is up versus -24.8% a few years ago. The consensus 12-month price target for Harrow is 70.38 USD, about 82.6% above where the stock trades today. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 33% above its 52-week low.
Harrow stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Harrow over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Harrow stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Harrow's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Harrow Price |
|---|---|
| 9/4/2026 | 38.54 USD |
| 9/3/2026 | 38.26 USD |
| 9/2/2026 | 39.05 USD |
| 9/1/2026 | 36.97 USD |
| 8/31/2026 | 36.91 USD |
| 8/30/2026 | 36.39 USD |
| 8/28/2026 | 37.58 USD |
| 8/27/2026 | 38.85 USD |
| 8/26/2026 | 39.33 USD |
| 8/25/2026 | 41.33 USD |
| 8/24/2026 | 39.50 USD |
| 8/21/2026 | 40.95 USD |
| 8/20/2026 | 42.06 USD |
| 8/19/2026 | 42.20 USD |
| 8/18/2026 | 38.52 USD |
| 8/14/2026 | 40.03 USD |
| 8/13/2026 | 38.87 USD |
| 8/12/2026 | 39.36 USD |
| 8/11/2026 | 39.42 USD |
| 8/10/2026 | 40.12 USD |
| 8/7/2026 | 40.44 USD |
| 8/6/2026 | 39.92 USD |
| 8/5/2026 | 39.84 USD |
| 8/4/2026 | 39.56 USD |
| 8/3/2026 | 39.09 USD |
| 7/31/2026 | 38.77 USD |
| 7/30/2026 | 38.94 USD |
| 7/29/2026 | 39.22 USD |
| 7/27/2026 | 37.99 USD |
| 7/23/2026 | 41.88 USD |
Harrow Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | 0.07 | 0.09 | 0.13 | 0.20 | 0.27 | 0.35 | 0.53 | 0.72 | 0.96 | 1.10 |
| 800.00 | 111.11 | 36.84 | 57.69 | 24.39 | -5.88 | 50.00 | 22.22 | 47.73 | 53.08 | 36.68 | 28.68 | 52.00 | 34.59 | 34.36 | 14.76 |
| 44.44 | 52.63 | 50.00 | 58.54 | 66.67 | 70.83 | 75.00 | 71.59 | 69.23 | 75.38 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 | 75.00 |
| 4.00 | 10.00 | 13.00 | 24.00 | 34.00 | 34.00 | 54.00 | 63.00 | 90.00 | 150.00 | 204.00 | 262.50 | 399.00 | 537.00 | 721.50 | 828.00 |
| -14.00 | -16.00 | -12.00 | -5.00 | -4.00 | – | 1.00 | 1.00 | – | 8.00 | 38.00 | 19.00 | 161.00 | 267.00 | 361.00 | 432.00 |
| -155.56 | -84.21 | -46.15 | -12.20 | -7.84 | – | 1.39 | 1.14 | – | 4.02 | 13.97 | 5.43 | 30.26 | 37.29 | 37.53 | 39.13 |
| -15.00 | -19.00 | -11.00 | 14.00 | – | -3.00 | -18.00 | -14.00 | -24.00 | -17.00 | -5.00 | -3.00 | 82.00 | 152.00 | 267.00 | 323.00 |
| 50.00 | 26.67 | -42.11 | -227.27 | – | – | 500.00 | -22.22 | 71.43 | -29.17 | -70.59 | -40.00 | -2,833.33 | 85.37 | 75.66 | 20.97 |
| 10.41 | 18.93 | 20.95 | 24.34 | 25.87 | 25.75 | 27.47 | 29.43 | 35.35 | 35.81 | 36.76 | 36.76 | 36.76 | 36.76 | 36.76 | 36.76 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Harrow generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Harrow retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Harrow's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Harrow has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Harrow's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Harrow stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow business model & stock analysis
Harrow SWOT Analysis
Strengths
Harrow Health Inc possesses several strengths, which contribute to its competitive advantage in the market. These strengths include:
- Strong brand reputation and recognition in the healthcare industry.
- Robust portfolio of high-quality pharmaceutical products.
- Effective distribution network ensuring wide market reach.
- Strong relationships with healthcare professionals and key stakeholders.
- Commitment to innovation and research to drive product development.
Weaknesses
Although Harrow Health Inc has demonstrated strengths, it also faces certain weaknesses, which need to be addressed for sustained growth. These weaknesses include:
- Relatively high dependence on a limited number of major customers.
- Inadequate geographical diversification leading to vulnerability in certain markets.
- Higher production costs compared to some competitors.
- Limited market share in specific therapeutic areas.
Opportunities
Harrow Health Inc can capitalize on various opportunities to expand its market presence and enhance profitability. These opportunities are:
- Increasing demand for specialized pharmaceutical products.
- Growing healthcare expenditure and favorable regulatory environment.
- Potential for strategic partnerships or acquisitions to broaden product offerings.
- Emerging markets providing untapped growth potential.
Threats
Harrow Health Inc must also be aware of potential threats that could hinder its progress. These threats include:
- Intense competition within the pharmaceutical industry.
- Changing industry regulations and compliance requirements.
- Risks associated with product safety and recalls.
- Economic fluctuations and healthcare cost containment measures.
Harrow Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow Segments
Harrow Revenue by Segment (1/4)
Max
Details
Harrow Revenue by Segment (2/4)
Max
Details
Harrow Revenue by Segment (3/4)
Max
Details
Harrow Revenue by Segment (4/4)
Max
Details
Harrow Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Harrow historical P/E ratio, EBIT multiple, and P/S ratio
Harrow annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Harrow shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Harrow stock splits
Current Harrow forecasts and price targets in September 2026
Analyst Price Targets 2026Harrow Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/11/2026 | Maintained | Buy | 52 | |
| 7/21/2026 | Maintained | Buy | 52 | |
| 5/13/2026 | Maintained | Overweight | 41 | |
| 5/12/2026 | Maintained | Buy | 52 | |
| 4/17/2026 | Maintained | Buy | 52 | |
| 4/7/2026 | Maintained | Buy | – | |
| 3/19/2026 | Maintained | Buy | – | |
| 3/18/2026 | Maintained | Buy | 52 | |
| 3/4/2026 | Maintained | Buy | – | |
| 3/4/2026 | Maintained | Overweight | 41 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Harrow Earnings Calls
Harrow Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/11/2026 | -0.18USD | - | 72.03 MUSD | - | 2026 Q2 |
| 5/11/2026 | -0.41USD | - | 53.47 MUSD | - | 2026 Q1 |
| 3/2/2026 | 0.38USD | - | 90.22 MUSD | - | 2025 Q4 |
| 8/11/2025 | 0.01USD | - | 67.32 MUSD | - | 2025 Q2 |
| 11/13/2024 | -0.05USD | - | 53.87 MUSD | - | 2024 Q3 |
| 5/9/2024 | -0.01USD | - | 43.49 MUSD | - | 2024 Q1 |
| 3/21/2024 | -0.05USD | - | 38.61 MUSD | - | 2023 Q4 |
| 11/13/2023 | 0.06USD | - | 29.28 MUSD | - | 2023 Q3 |
| 8/7/2023 | 0.04USD | - | 27.76 MUSD | - | 2023 Q2 |
| 5/3/2023 | 0.03USD | - | 26.44 MUSD | - | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Harrow stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Harrow shareholder structure
| % | Name |
|---|---|
10.56841% | |
7.70455% | |
6.94430% | |
6.10483% | |
5.20618% | |
5.01378% |
Harrow Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
53.60% | SEC ↗ | |
53.40% | SEC ↗ | |
20.70% | SEC ↗ | |
12.30% | SEC ↗ | |
11.40% | SEC ↗ | |
11.40% | SEC ↗ | |
11.22% | SEC ↗ | |
10.69% | SEC ↗ | |
10.34% | SEC ↗ | |
8.94% | SEC ↗ |
Harrow Executives and Management Board
9 members · avg. age 57 · 22 % women
Mr. Mark Baum (52)
Chairman of the Board, Chief Executive Officer · since 2011
1.36 M USD
Management
Mr. Andrew Boll (42)
President, Chief Financial Officer, Company Secretary
Mr. Frank Mullery
Chief Executive Officer of ImprimisRx
Mr. Randall Pollard (53)
Chief Accounting Officer
Mr. Amir Shojaei (57)
Chief Scientific Officer
Mr. Patrick Sullivan
Chief Commercial Officer
Board of Directors
Dr. Adrienne Graves (71)
Independent Director
Mrs. Lauren Silvernail (67)
Independent Director
Mr. Perry Sternberg (56)
Lead Independent Director
Harrow Supply Chain
Harrow Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.56 | 0.22 | 0.70 | ||
| 2 | 0.73 | 0.70 | 0.30 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.89 | 0.65 | -0.25 | ||
| 2 | 0.48 | 0.50 | -0.20 |
Frequently asked questions about Harrow
Harrow Health Inc is a pharmaceutical company that operates on a unique business model. They specialize in acquiring and commercializing branded prescription drugs. By acquiring smaller pharmaceutical companies and their products, Harrow Health Inc focuses on improving patient access to vital medications. Their business strategy involves developing partnerships, managing intellectual property, and conducting research to ensure the availability of necessary medications. Through this model, Harrow Health Inc aims to address unmet medical needs and offer innovative solutions to patients. This approach enables the company to play a significant role in the pharmaceutical industry and deliver impactful healthcare products.
Harrow Health Inc is primarily active in the healthcare industry.
The main competitors of Harrow Health Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Novartis AG.
Harrow Health Inc, formerly known as Imprimis Pharmaceuticals, is a pharmaceutical company specializing in the development and commercialization of innovative therapeutic products. Founded in 2006, the company initially focused on providing compounded medications to patients and physicians. Over the years, Harrow Health Inc expanded its portfolio, acquiring multiple ophthalmology-focused businesses and broadening its reach within the eye care industry. Today, the company's offerings include both FDA-approved and compounded medications, along with proprietary formulations and drug delivery technologies. Harrow Health Inc continues to demonstrate its commitment to improving patient access to high-quality, affordable healthcare solutions within the pharmaceutical sector.
Harrow Health Inc has accomplished several significant milestones in its history. Firstly, the company successfully expanded its pharmaceutical portfolio by acquiring Imprimis Pharmaceuticals, which greatly enhanced its product offering and market presence. Additionally, Harrow Health Inc implemented strategic partnerships and collaborations to further its growth and innovation. The company also achieved financial milestones by consistently delivering positive financial results and increasing its revenue over time. Furthermore, Harrow Health Inc demonstrated its commitment to advancing patient care by successfully launching innovative drugs and expanding its prescription services. These achievements highlight Harrow Health Inc's continuous progress, strong market position, and dedication to improving healthcare outcomes.
Harrow Health Inc is primarily present in the United States.
Harrow Health Inc represents values of innovation, patient care, and ethical practices. The company strives to develop and deliver high-quality medications and healthcare solutions that improve patient outcomes and advance medical treatments. Harrow Health Inc is committed to providing accessible and affordable pharmaceuticals while maintaining strict regulatory compliance. With a focus on research and development, the company aims to address unmet medical needs and introduce pioneering therapies to enhance overall patient well-being. Harrow Health Inc's corporate philosophy revolves around integrity, transparency, and putting patients first, driving its mission to make a significant impact in the healthcare industry.
Analysts currently set an average price target of 72.13 USD for the Harrow stock (median: 70.38 USD), implying +93.5 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the Harrow stock: 13 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Harrow to generate revenue of 350.67 M USD and earnings per share of -0.09 USD.
Converted at the current exchange rate, the Harrow share trades at 33.16 EUR (38.54 USD).
The Harrow share (HROW) is listed on 1 stock exchanges, including: NASDAQ (HROW).
Harrow Health Inc is a company that specializes in the development, marketing, and sale of high-quality pharmaceuticals and medical devices. Its business model is focused on the field of ophthalmology medicine, which is a specialized niche with a high demand for innovative products and services. The company offers its products and services in various areas, including the development of eye drops and steroids. It works closely with doctors and other medical professionals to understand the needs of patients in this area and develop innovative solutions that deliver better results for patients. Another important area in which the company operates is the production of eye implants and lenses suitable for patients with a variety of eye conditions. The different types of lenses range from intraocular lenses for vision correction to multifocal lenses for older patients. Harrow Health is also active in the production of medical devices and offers a wide range of products that can be used for eye treatment. The company manufactures medical instruments for use in surgeries, diagnostic instruments for early detection of eye diseases, and even devices for data processing and analysis. One of Harrow Health's standout products is the Buccolam medication, which was developed for the treatment of epilepsy in children and adults. Buccolam is a fast-acting seizure medication offered in a rapidly dispersible formulation and is an incredibly effective treatment for seizures. Overall, the company relies on a diversified business model to ensure that it can respond to market needs while also building a stable and sustainable business. By focusing on multiple areas of ophthalmology medicine and offering a wide range of products and services, Harrow Health ensures that it can serve a variety of customers and operate very successfully in the market. In summary, Harrow Health is a strong company that specializes in pharmaceutical and medical technology for eye care. With its wide range of products such as eye drops, implants, and medical instruments, the company ensures that it can respond to the needs of patients in this field and remain relevant to ophthalmology medicine.
The expected revenue of Harrow is 350.67 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Harrow is -3.40 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Harrow is currently -416.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Harrow stock.
The price-to-sales ratio (P/S) of Harrow is currently 4.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Harrow stock.
The Eulerpool Quality Score for Harrow is 5/10.
The ISIN of Harrow is US4158581094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Harrow is A2PBJD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Harrow is HROW. The ticker symbol is used to trade Harrow shares on the stock exchange.
Harrow paid dividends every year for the past 0 years.
Harrow is assigned to the 'Health' sector.
The dividends of Harrow are distributed in USD.
Harrow stock
Harrow Peer Group
Harrow Ticker
Harrow FIGI
All fundamentals and in-depth analysis of Harrow
Our stock analysis for Harrow stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Harrow. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.